Compare Ascendis Pharma A/S (ASND) vs iShares JPMorgan USD Emerging Markets Bond ETF (EMB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs iShares JPMorgan USD Emerging Markets Bond ETF — how do they compare? Ascendis Pharma A/S trades at $270.45 (market cap $17.74B), while iShares JPMorgan USD Emerging Markets Bond ETF trades at $96. The key difference: Ascendis Pharma A/S is trading nearer its 52-week high, iShares JPMorgan USD Emerging Markets Bond ETF nearer its low. Which is the better fit depends on your goals.
| ASND | EMB | |
|---|---|---|
Market Cap | $17.74B | — |
Sector | Health | Fixed Income |
52-Week High | $277.18 | $97.74 |
52-Week Low | $163.32 | $91.52 |
Enterprise Value | $18.11B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
EMB trades at $95.99, showing minimal daily movement with a 0.03% gain. Technical indicators signal a bearish trend, while oscillators remain neutral. Recent corporate actions include scheduled dividend payments for mid-2026. News coverage highlights emerging market bond risks and Federal Reserve policy impacts on performance.
The outlook for EMB is cautious due to emerging market sovereign default risks and interest rate sensitivity. Investment opportunity lies in its yield for income-focused investors, but macroeconomic volatility and geopolitical tensions present significant headwinds for sustained appreciation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About iShares JPMorgan USD Emerging Markets Bond ETF
EMB invests in U.S. dollar-denominated sovereign debt from emerging market countries. It provides exposure to government bonds from dozens of nations like Turkey, Mexico, and Brazil, offering a way to seek higher yields and geographic diversification.
Read more on EMB →
